SeromYx and ACROBiosystems Partner for Anti-CD20 Monoclonal Antibody Profiling

NEWARK, Del., Sept. 29, 2024 – SeromYx Systems, known for its advanced immunology technology, and ACROBiosystems, a leader in life science solutions, have jointly published a study on the functional profiling of anti-CD20 monoclonal antibodies (mAbs). This research leverages SeromYx's biophysical and cellular Fc-effector function platform along with ACROBiosystems' recombinant human full-length CD20 virus-like particles (VLPs), aiming to provide deeper insights into the therapeutic safety and efficacy of these mAbs.

CD20 is an important target in the treatment of B-cell malignancies and autoimmune diseases. It is selectively expressed on B-cells, enabling effective B-cell depletion while maintaining long-term immune memory. The study conducted a comparative analysis of the biophysical binding and immune effector functions of Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), offering an in-depth look at their mechanisms of action.

Lenny Moise, VP of Research at SeromYx, emphasized the study's significance, noting, "This study reinforces the value of comprehensive Fc effector profiling as crucial for understanding the safety and efficacy mechanisms of mAbs. It also has implications for developing new anti-CD20 mAbs."

Throughout the study, the anti-CD20 mAbs exhibited robust binding profiles and distinct Fc-effector functions. Notably, the collaboration uncovered new Fc-effector functions, such as antibody-dependent neutrophil and eosinophil phagocytosis activities. These findings expand the understanding of how these mAbs interact with immune cells, which could influence their effectiveness in various clinical contexts.

John Miao, Senior VP at ACROBiosystems, highlighted the importance of these findings, stating, "This collaborative study with SeromYx is a significant step in exploring the wide applications of our human CD20 full-length VLP. We are excited to see how our full-length transmembrane proteins contribute to a deeper understanding of antibody drug efficacy, driving forward innovations in immunology."

SeromYx Systems specializes in high-throughput cell and bead-based assays combined with machine learning computational analysis to enhance the design and development of therapeutic monoclonal antibodies. By profiling functional interactions between antibodies and innate immune cells, the company aids biotechnology and pharmaceutical firms in developing targeted therapies with precision. SeromYx Systems' platform offers extensive Fc effector function profiling to identify antibody functions for targeting pathogens, infected cells, or tumors.

The company provides a comprehensive range of biophysical and functional assays to support the entire lifecycle of monoclonal antibody development, from candidate selection to IND and CMC filing. With a GCLP-certified platform and robust data interpretation capabilities, SeromYx Systems is a trusted partner in developing monoclonal therapies that address critical health challenges and unmet medical needs.

ACROBiosystems, a subsidiary of ACROBiosystems Group, is dedicated to being a cornerstone of the global biopharmaceutical and health industries. The company spans the globe and has established numerous long-term partnerships with leading pharmaceutical enterprises and academic institutes. ACROBiosystems offers innovative tools and solutions for overcoming challenges from discovery to clinical application. Their portfolio includes recombinant proteins, antibodies, assay kits, GMP-grade reagents, and custom services, empowering scientists and engineers to accelerate the development of new, effective, and affordable medicines.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!